2024.7.15æ¦ç¥è¨äº 親åã®ã«ããµã³ã¹ãã«ã¨ã«ã«æ²³ç«¥ã«å°å°ç ´ãã«â¦â¦ï¼ã¢ãã³ï¼ï½å²©SHOWã®ããã¤ãªã¼ã»ãããã
Su-25æ»ææ©ãä½ç©ºã§æ¿ããæ©åãè¡ããªããé£ã³å»ã£ã¦ãã£ãã æ é·ã®åèçãæ¦å ´ã«ãªã£ãã®ã ã ãããã夢ãè¦ããããã®ä¸çã®çé ã«ãã®çæ¸ç£ç£ã¨ä¼è«ããã¦ãããã§ãè»é½ã¨ãã¦ã®åèçãã¨ãã£ã話ãããå¤ã ã£ããããä½æ ãããã夢ã«ãªã£ããã¯æããã ã ããããæ²ããã£ãã åã¯å°ãè¾¼ã¿å ¥ã£ãçãåéã®éä¸ã«ããé§è»å ´ã¾ã§è»ãåãã«è¡ã£ã¦ããã®éä¸ã§èªåã®çã¾ãã¦çããåèçã®ç©ºããã·ã¢ã®æ»ææ©ãé£ãã§ãããããã³ã³ã¯ãªã¼ãã®å£ã«é¡ãã¤ãã¦ãªã¤ãªã¤æ³£ããã æ¡å¤ã¨ãããããã¨ãããããªãã¦ã人éã¯ãçãã¨ããå¸ãã¨ãã¾ã§éãã¦æ¥ãªãã¨æ¦ã®æ¨ç¦è¦ããã®ãå®æã§ããªãã®ãããããªãã§ããã ããã«ãã¦ãåã¯æ é·ãæãã§ããããã§ããã£ã±ãæ¦å ´ã«ãªã£ããæ³£ããã ãªãã
å覧強è¨ã®èªæ¸å®¶ãèªæ¸ç¿ãå¤ä»æ±è¥¿ã®åèã§èããè¨å¤§ãªç¥èãçãããããã¾ã§ãã¢ã¤ãã¢å¤§å ¨ããåé¡è§£æ±ºå¤§å ¨ããªã©ã®ãããä½ãä¸ã«åºãã¦ããããããªå½¼ã®æ°åãç¬å¦å¤§å ¨ãã¯ãããã¾ã§èªåã§å¦ãã§ããå½¼ã®èãæ¹ã®ã¨ãã»ã³ã¹ãè©°ã¾ã£ã¦ãããç¬å¦ã«ã¨ã©ã¾ãããæ¥å¸¸çæ´»ããã¸ãã¹ãªã©æ§ã ãªå ´é¢ã§å¿ç¨å¯è½ãªã©ã¤ãããã¯ãããç¬å¦å¤§å ¨ãããç´¹ä»ããã ãä¸æ¥å主ã¨æ±ºå¥ããæ¹æ³ããä¼æãããååã®è¨äºã¯ãã¡ã å¤ä»£ã®ãªã·ã¢ä»¥æ¥ã®é£å ãããã½ã¯ã©ãã¹ããã£ããããªãã¯ããããä½ã§ãããããªãã«ããããããã£ã¦ããªãã¨ããããã©ããã£ã¦ãããæ¢æ±ãããã¤ããã§ããï¼ï¼ä¸ç¥ï¼ãããã¯ã幸ãã«ãã¦ããªããããããããå½ã¦ãã¨ãã¦ããããã ã¨ãããã¨ãã©ããã¦ããªãã«ãããã§ããããââãã¨ãã¨ããªãã¯ãããç¥ããªãã£ãã¯ããªã®ã« ãã©ãã³ãã¡ãã³ãï¼è¤æ²¢ä»¤å¤«è¨³ã»å²©æ³¢æåº«ï¼ ãã©ãã³ã®å¯¾è©±ç¯ãã¡ãã³ãã«ã¯ããã®ãã
å»å¦ã®å°å¹³ç· 第133å·ãæ°åã³ããã¦ã¤ã«ã¹ã¨éºä¼å æ°åã³ããã¦ã¤ã«ã¹ã¯ä¸çä¸ã«é©ç°çãªå¢ãã§åºãã£ã¦ãã¾ããä»ãæã ãåªåãã¹ããã¨ã¯ããã®æ¡æ£ãã§ããéãæå¶ãããã®éã«äºé²è¬ãæ²»çè¬ãã¯ã¯ãã³ãéçºãããã¨ã§ãã å¤ãã®å½ã ã«åºããã人å£ãæ¸å°ãããã»ã©ã®æ»äº¡çã示ããä¾ã¨ãã¦ã14ä¸ç´ã®ã¨ã¼ãããã«åºãã£ããã¹ãã20ä¸ç´ã®åé ã«èµ·ããã¹ãã¤ã³é¢¨éªãããã¾ãããã以å¤ã«ããã³ã¬ã©ã天ç¶çãçµæ ¸ãªã©ææçã人é¡ã«å¤§ããªå½±é¿ãä¸ããä¾ã¯æ°ç¥ããããã¾ãã ãã®å½±é¿ã¯éºä¼åã«ãå»ã¾ãã¦ãã¾ããä¾ãã°ã第6æè²ä½çè ã«åå¨ããHLA (human leukocyte antigen)éºä¼å群ã¯éå»ã®ææçã®å½±é¿ã大ããåããéºä¼åã¨èãããã¦ãã¾ãããã以å¤ã«ãå ç«ã°ãããªã³éºä¼åãTç´°èå容ä½éºä¼åãææçã«å¤§ããå½±é¿ãããã¨èãããã¾ããããããã®éºä¼åã¯ä½å ã§å¤åãããã¨ãã§ãï¼ä½
ããã®èµ¤è¡çã®è¡æ¶²åã«ã¯AãBãOã®3種é¡ãããã¾ããããªã3種é¡ããã®ãï¼ãã®åããªã©ã¯è§£æããã¦ããããä¸è¬ã«ç¥ãããâæ§æ ¼âã¨ã®é¢é£æ§ã¯ç§å¦çã«ã¯å ¨ã証æããã¦ãã¾ããããã赤è¡çè¡æ¶²åã§å¯ä¸é¢é£æ§ãããã¨ããã¦ããã®ããèããã®ä¸»åå ã§ãããããªèææã¸ã®é¢ä¸ã¨è¨ããã¦ãã¾ãã ä¸æ¹ã§ããç½è¡çã®è¡æ¶²åãã¨ãã¦ç¥ãããHLAï¼Human Leukocyte Antibody=ããç½è¡çæåï¼ã¯ç´16,000種ã®å¤åæ§ãæããå¤ãã®å½¹å²ãããäºãåãã£ã¦ãã¦ãã¾ããHLAéºä¼åã¯ãããããã²ãã ã®ä¸ã§æãå¤ãå¤åã¨ãé常ã«è¤éãªã·ã¹ãã ãæã¤éºä¼åãªã®ã§ãã HLAç 究ã®æ´å² HLAã«é¢ããç 究ã®å§ã¾ãã¯1960年代ã«é¡ãã¾ããèå¨ã移æ¤ããéãå ç«åå¿ãèµ·ããæ絶ããã¾ãããæ°ç¾ï½æ°å人ã«ä¸äººåå¨ããHLAåãä¸è´ããããã®èå¨ã§ããã°å®çãããã¨ãåããã¾ãããHLAã¯å½åã移æ¤
AASJãã¼ã ãã¼ã¸ > æ°çæ å ± > è«æã¦ã©ãã > ï¼æï¼ï¼æ¥ãæ°åã³ããã¦ã¤ã«ã¹ã¸ã®æåæ§ã«ã¤ãã¦ã®ç 究ãå°ããã¤å§ã¾ã£ã¦ããï¼ï¼æï¼ï¼æ¥å· J.Virology ãªã³ã©ã¤ã³æ²è¼è«æï¼ ä»æ¥ã®æ¥æ¬çµæ¸æ°èã§ã¯æ°åã³ããã¦ã¤ã«ã¹ã®æææåæ§ããç æ°ã®éç度ã¨ç¸é¢ããéºä¼åãç¹å®ããããã®ã²ãã ç 究ã³ã³ã½ã¼ã·ã¢ã ãå§ã¾ã£ããã¨ãå ±éããã¦ããï¼https://www.nikkei.com/article/DGXMZO58510850V20C20A4EA1000/ï¼ããã ããã®æ§ãªã³ã³ã½ã¼ã·ã¢ã ã¯ããã«ç²¾åº¦ã®é«ãç 究ãç®æã話ã§ãææè ãï¼ï¼ï¼ä¸äººã«éããããã¨ããæ°åã³ããã§ã¯ããããæ©ãææããã²ãã ç 究ã¯è¡ããã¦ããã¨æ³åãããããæã£ã¦æ¯æ¥ãPubMedæ¤ç´¢ãµã¤ãã§ãCovid-19 and SNPã¨ãGWASã¨ããæ¤ç´¢ãã¦ããããä»ã®ã¨ããã¯æ確ãªhitã¯ãªããå°ãç¯å²ãåºãã¦
æ¥æ¬(ã¢ã¸ã¢)ã®æ°åã³ããææè ãéçè ãæ»è ã欧米ããã¯ããã«å°ãªãçç±ã¯HLAã¨ä»®å®ããã¨ãã³ãã·ã£ã«ã¯ã¾ã ãããã主å¬ãã¦ãã¾ãã21ä¸ç´ãçãæ®ãããã®ãæ°¸æ±ãèã®ç©´å¡¾ãã§ã¯ãï¼æããã®å¡¾çãåéãã¦ãã¾ããã³ããç¦ã®éãå¸æè ã¯æ¯æ30åããããã¨1:1ã§zoomã§ãã¬ã¹ããã§ãã¾ãã ã¾ããææ¥5/4ã«ã¯æ°¸æ±å¡¾ã®ã¡ã³ãã¼ã§ããé³åå¤åè°é¢è°å¡ã¨ããå®ä½ç¾å ¸ä¹ã¨ãã¨ãã駿ã®ããããæ¿æ²»ããµãã³(ãã¾æ°è¦ã¡ã³ãã¼ã¯åéåæ¢ã ã£ã¦)ã¨ã®ååã§ããã¾ãæ¿æ²»ã«åå ããã«ã¯ãã¨ããã¤ãã³ããZOOMã§éå¬ãå®å¡ã¯100åã§ãã®ã§ãã²ãåå ä¸ããã ããã¾ã§ä»®èª¬ã§ãããªãã¨ã³ããªã¼ã§æ¤è¨¼ã¯ä¸çä¸ã§ãã¦ããæä¸ã§ãã®ã§ãããåæã«ãèªã¿ãã ããã ã¾ãããã¼ã¯ã¢ã¦ãã¨æ¸ãã¦ããã®ã¯æ£ç¢ºã«ã¯ãå¢å çãéããã§ãã®ã§ãäºæ¿ãã ãã æ¨æ¥ã®ã¨ã³ããªã¼ã§ãææ¥ã¯å°é家ä¼è°ã®è³æã解説ããããã£ã¦æ¸ã
ãç¬ãã³ã³ããã¦ã¼ãã³ã©ãã·ã¥ã¢ã¯ã¼ã®ææ¬å¤§è¼ããæ¥æ¬ã®è¸è½çãé£ã³åºããã¢ã¡ãªã«ã§ããã¥ã¼ãããã¨ãæºåãã¦ããã2020年度ä¸ã®æ¸¡ç±³ãç®æããç¸æ¹ã®ä¸å·ãã©ãã¤ã¹ãåæ¬èæ¥ã¨è©±ãåããé²ãã¦ããã ã¢ã¡ãªã«ã§ææ¦ããã®ã¯ãèå°ã®ä¸ã«ç«ã¡ãªãããä¸äººåãã§ç¬ããããã¹ã¿ã³ãã¢ããã³ã¡ãã£ããã¿ãã¼ãæããæäºãã¿ãã¾ããç«ã¦ããæ¥æ¬ã§ã®ææ¬ã®è¸é¢¨ãçãããã¹ã¿ã¤ã«ã ã
ããªãã£ãã·ã¥ã»ã¨ã¢ã¦ã§ã¤ãºï¼ï¼¢ï¼¡ï¼ãã¼ã¤ã³ã°ï¼ï¼ï¼åæ©ï¼ï¼æï¼ï¼æ¥/Nicolas Economou/NurPhoto via Getty Images ãã³ãã³ï¼ï¼£ï¼®ï¼®ï¼Â è±ããªãã£ãã·ã¥ã»ã¨ã¢ã¦ã§ã¤ãºï¼ï¼¢ï¼¡ï¼ã®ãã¥ã¼ã¨ã¼ã¯çºãã³ãã³è¡ãã®æ 客æ©ï¼ãã¼ã¤ã³ã°ï¼ï¼ï¼åæ©ï¼ãï¼æ¥ã大åä½æ°å§ãã·ã¢ã©ãã®ããããæ´é¢¨ã«ä¹ã£ã¦é³é並ã¿ã®é度ãéæãããã®è·¯ç·ã®é£è¡æéã¨ãã¦ã¯å²ä¸æçã¨ãªãï¼æéï¼ï¼åã§ç®çå°ã«å°çããã å便ã¯äºå®ããï¼æéè¿ãæ©ãï¼æ¥ååï¼æï¼ï¼åããã³ãã³ã®ãã¼ã¹ãã¼ç©ºæ¸¯ã«å°çããããã©ã¤ã追跡ãµã¼ãã¹ã®ããã©ã¤ãã¬ã¼ãã¼ï¼ï¼ãã«ããã¨ãåæ©ã®é度ã¯æé«ã§æéï¼ï¼ï¼ï¼ããã«éãã¦ããã åãµã¼ãã¹ã«ããã°ããã³ãã³ã¨ãã¥ã¼ã¨ã¼ã¯ãçµã¶ä¾¿ã®å¹³åé£è¡æéã¯ï¼æéï¼ï¼åã BA便ã®æ°åå¾ã«ã¯ãã´ã¡ã¼ã¸ã³èªç©ºã®ä¾¿ï¼ã¨ã¢ãã¹ï¼¡ï¼ï¼ï¼ï¼ããã¼ã¹ãã¼ç©ºæ¸¯ã«å°çãããããã©ã¤ãã¬ã¼ãã¼ï¼
æµ·å¤ãæ¥æ¬ã§æ´»åãããã¼ã©ã®æ¥ã ã®ãã£ã¦ã¿ããäºãªã©ãé ä¿¡ãã¸ã¡ãªäºãããããããäºã¾ã§ã¢ã¯ãã£ãã«æ¥½ããéãããã¼ã©ã®æ¥å¸¸ãæ°æ¥½ãªæãã§æ¥½ããã覧ã«ãªã£ã¦ãããã¼ã«ãªã£ã¦ããã ããã°ããããã§ã
As an anonymous user you have been blocked for going over 500 API calls per 24 hour period. Please create a free account at https://accounts.muckrock.com/accounts/signup/?intent=documentcloud in order to increase your limit. If you believe you are seeing this message in error, please contact [email protected]
é侵襲çæ¹æ³ã¯è³ã®æ´»åãèªã¿åããã ãã§ãªããè³ã®æ´»åãæ´»æ§åããããã¨ãã§ãããé侵襲çæ¹æ³ã®æ¹ã容æã ããæ°ããªãã¬ã¤ã¯ã¹ã«ã¼ã«ã¯ãè³å ã®ããæ·±ãã¨ããã«ãããã¥ã¼ãã³ã¨ã®ã³ãã¥ãã±ã¼ã·ã§ã³ã®å¯è½æ§ãããã¨Heæ°ã¯èªã£ãã Neuralinkã®æ¹æ³ãæ©è½ããã¨ãã¦ããããã«ãã©ã³ã¹èªã話ãè½åããã¦ã³ãã¼ãã§ããããã«ãªãããã§ã¯ãªããå社ã®æåã®ç®æ¨ã¯ããªãéå¿çãªãã®ã ããNeuralinkã®ä¿¡å·ãè³ãç解ããããè¨ç·´ããã®ã¯ç°¡åã§ã¯ãªãã¨ãå社ã®å ±ååµæ¥è ã§ç¤¾é·ã®Max Hodakæ°ã¯èªã£ãããå¦ç¿ã«ã¯æéãããããã¿ããã¿ã¤ãã³ã°ããã¢ãæ¼å¥ãç¿å¾ãããããªãã®ã ãã¨ããã èè åããElon Muskã¨Neuralinkãã¨ãªã£ã¦ããç 究è«æï¼æ»èªä»ãã®å°éèªã«æ²è¼ããã¦ãããã®ã§ã¯ãªãï¼ã®ä¸ã§ãNeuralinkã¯ããºãã使ã£ãæè¡å©ç¨ã®é²æ©ãç´¹ä»ãããããã±ã¼ã¹ã§ã¯ãå°ç·
å®å®ã¤ã³ã¿ã¼ããããç«æã®ã³ããã¼ã«ââãæã ãã¯ã¯ã¯ã¯ãããæ§æ³ãã¶ã¡ä¸ããã¤ã¼ãã³ã»ãã¹ã¯ï¼åååç §ï¼ããã¾ãã¹ã©ãã¹ãã¼ã¹Xãããã¦ãã¹ã¯èªèº«ã«ã大ããªå¤åãèµ·ãããã¨ãã¦ãããæ¬æ ¼ä¼è¨ãã¤ã¼ãã³ã»ãã¹ã¯ æªæ¥ãåµãç·ãã®èè ãããã¹ã¯ã®ææ°ååãä¼ããã ãã±ããççºäºæ ãã§ã«è¡æãæã¡ä¸ããããã®ãã±ããä¼ç¤¾ãæã£ã¦ãã¦ãè³éã潤沢ã«ããç·ãããã«ããã®ã¯ç¢ºãã ããããªç·ãã©ããªæ§æ³ãã¶ã¡ä¸ãã¦ã人ã ã¯æ¬æ°ã§è³ãå¾ãã ã ãããããããã¤ãªããã£ã¨æåããããã¨æå¾ ããã®ãç¡çã¯ãªãããå®ã¯æ§æ³èªä½ã¯ãã£ã¨ãã¯ã¯ã¯ã¯ãããããªè©±ã§ããªãã ãããããã¡ããããã§ããç¶æ ã«ãªã£ã¦ããã®ã ãä¾ãã¦ãããªããä¸æ¥ä¸æ©ã飲ããæãã®ã©ãã¡ããé¨ããåãã¦å³ãããå¼·ãé ãé£ãã£ã¦ãã£ãããã¤ã«ãªã£ã¦ãããããã¨ãç¸æã誰ã§ãããã¨çµ¶ä¸ã®ç¾å¥³ï¼ãããã¯æé«ã®äºæç®ï¼ã«è¦ãã¦ã¡ãã¡ãã«ãªã£ã¦
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
å¦çãå®è¡ä¸ã§ã
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}